Cargando…

Long-term safety and efficacy of insulin degludec in the management of type 2 diabetes

Insulin degludec (IDeg) is a novel antiglycemic agent belonging to the therapeutic class of ultra-long duration basal insulin analogs. Its half-life and duration of action are 25 hours and 42 hours, respectively. This pharmacodynamic profile leads to a strict dosing schedule, ie, IDeg is injected at...

Descripción completa

Detalles Bibliográficos
Autores principales: Thuillier, Philippe, Alavi, Zarrin, Kerlan, Véronique
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4598200/
https://www.ncbi.nlm.nih.gov/pubmed/26457056
http://dx.doi.org/10.2147/DMSO.S54953
_version_ 1782394051542122496
author Thuillier, Philippe
Alavi, Zarrin
Kerlan, Véronique
author_facet Thuillier, Philippe
Alavi, Zarrin
Kerlan, Véronique
author_sort Thuillier, Philippe
collection PubMed
description Insulin degludec (IDeg) is a novel antiglycemic agent belonging to the therapeutic class of ultra-long duration basal insulin analogs. Its half-life and duration of action are 25 hours and 42 hours, respectively. This pharmacodynamic profile leads to a strict dosing schedule, ie, IDeg is injected at the same time each day to ensure optimal biological action and consistent glycemic control. According to the literature, IDeg provides glycemic control and nocturnal hypoglycemia reduction comparable with other long-acting analogs in type 2 diabetes mellitus. The risk of severe hypoglycemic episodes seems also to be reduced when using IDeg therapy; however, long-term follow-up is warranted for monitoring of possible but relatively infrequent adverse events. IDeg is also available in combination with aspart insulin and with liraglutide. The above preparations have been approved by the European Medicines Agency and other national health authorities. In 2012, the US Food and Drug Administration asked for a complementary study on IDeg-associated cardiovascular risk. Future prospective evaluation of large cohorts of patients with type 2 diabetes mellitus treated with IDeg, with long-term follow-up, can provide further relevant information on the safety of IDeg therapy.
format Online
Article
Text
id pubmed-4598200
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-45982002015-10-09 Long-term safety and efficacy of insulin degludec in the management of type 2 diabetes Thuillier, Philippe Alavi, Zarrin Kerlan, Véronique Diabetes Metab Syndr Obes Review Insulin degludec (IDeg) is a novel antiglycemic agent belonging to the therapeutic class of ultra-long duration basal insulin analogs. Its half-life and duration of action are 25 hours and 42 hours, respectively. This pharmacodynamic profile leads to a strict dosing schedule, ie, IDeg is injected at the same time each day to ensure optimal biological action and consistent glycemic control. According to the literature, IDeg provides glycemic control and nocturnal hypoglycemia reduction comparable with other long-acting analogs in type 2 diabetes mellitus. The risk of severe hypoglycemic episodes seems also to be reduced when using IDeg therapy; however, long-term follow-up is warranted for monitoring of possible but relatively infrequent adverse events. IDeg is also available in combination with aspart insulin and with liraglutide. The above preparations have been approved by the European Medicines Agency and other national health authorities. In 2012, the US Food and Drug Administration asked for a complementary study on IDeg-associated cardiovascular risk. Future prospective evaluation of large cohorts of patients with type 2 diabetes mellitus treated with IDeg, with long-term follow-up, can provide further relevant information on the safety of IDeg therapy. Dove Medical Press 2015-10-01 /pmc/articles/PMC4598200/ /pubmed/26457056 http://dx.doi.org/10.2147/DMSO.S54953 Text en © 2015 Thuillier et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Thuillier, Philippe
Alavi, Zarrin
Kerlan, Véronique
Long-term safety and efficacy of insulin degludec in the management of type 2 diabetes
title Long-term safety and efficacy of insulin degludec in the management of type 2 diabetes
title_full Long-term safety and efficacy of insulin degludec in the management of type 2 diabetes
title_fullStr Long-term safety and efficacy of insulin degludec in the management of type 2 diabetes
title_full_unstemmed Long-term safety and efficacy of insulin degludec in the management of type 2 diabetes
title_short Long-term safety and efficacy of insulin degludec in the management of type 2 diabetes
title_sort long-term safety and efficacy of insulin degludec in the management of type 2 diabetes
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4598200/
https://www.ncbi.nlm.nih.gov/pubmed/26457056
http://dx.doi.org/10.2147/DMSO.S54953
work_keys_str_mv AT thuillierphilippe longtermsafetyandefficacyofinsulindegludecinthemanagementoftype2diabetes
AT alavizarrin longtermsafetyandefficacyofinsulindegludecinthemanagementoftype2diabetes
AT kerlanveronique longtermsafetyandefficacyofinsulindegludecinthemanagementoftype2diabetes